Does prolonged clopidogrel therapy improve outcome in patients with drug-eluting or bare-metal stents?
Joost Daemen* and Patrick W Serruys
Correspondence *Thoraxcenter Erasmus Medical Center, Room Fd217, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
Email j.daemen@erasmusmc.nl
This article has no abstract so we have provided the first paragraph of the full text.
First of all, let us congratulate Eisenstein et al. on their remarkable investigation, which shows that prolonged clopidogrel use may reduce the risk of death and MI in patients treated with DESs. Despite a limited long-term follow-up (44% of the DES patients at-risk at 2 years) and a relatively small sample size in the DES group, the use of landmark analyses in the methodology is an original approach. We believe, however, that only including patients event-free at 6 and 12 months in the analysis carries some inherent limitations.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
